• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在住院环境中,通过皮下静脉港导管在植入当日开始化疗似乎是安全的。

It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting.

作者信息

Ozdemir Nuriye Yildirim, Abali Hüseyin, Oksüzoğlu Berna, Budakoğlu Burçin, Akmangit Ilkay, Zengin Nurullah

机构信息

Medical Oncology Clinic, Ministry of Health Ankara Numune Research and Training Hospital, Ankara, Turkey.

出版信息

Support Care Cancer. 2009 Apr;17(4):399-403. doi: 10.1007/s00520-008-0498-x. Epub 2008 Sep 2.

DOI:10.1007/s00520-008-0498-x
PMID:18762993
Abstract

GOALS

It is generally recommended to wait for at least 24 h before starting chemotherapy after implanting venous port catheters (VPC). Our aim was to evaluate whether it is safe to start chemotherapy on the day of implantation.

PATIENTS AND METHODS

One hundred eighty patients who had to be given chemotherapy on the day of VPC implantation at our institution from June 2005 to April 2007 were included.

MAIN RESULTS

Of patients, 122 were male (67.8%) and median age was 55 years. Majority (133, 72.8%) had colon and gastric adenocancer. Median time to chemotherapy onset from VPC implantation was 102 min (minimum-maximum, 12-402). One hundred sixty-four (91.1%) received prolonged chemotherapy infusions beyond 48 h. No life-threatening acute complications like pneumothorax and hemothorax developed. In one patient extravasation (empty saline extravasation secondary to wrong insertion of the needle), in 17 (9.4%) pain, and in 41 (22.8%) minor bleeding as echymosis were seen. Thrombosis developed in 11 (6.1%). Reasons for VPC removal were thrombosis (2), sepsis (2), cellulitis (1), skin dehiscence (1), and patient will (1).

CONCLUSION

Chemotherapy administration immediately after VPC implantation appears safe without increased acute and chronic complications in inpatient setting.

摘要

目标

一般建议在植入静脉港导管(VPC)后至少等待24小时再开始化疗。我们的目的是评估在植入当天开始化疗是否安全。

患者与方法

纳入了2005年6月至2007年4月在我院必须在VPC植入当天接受化疗的180例患者。

主要结果

患者中,122例为男性(67.8%),中位年龄为55岁。大多数(133例,72.8%)患有结肠和胃腺癌。从VPC植入到开始化疗的中位时间为102分钟(最短 - 最长,12 - 402分钟)。164例(91.1%)接受了超过48小时的延长化疗输注。未发生危及生命的急性并发症,如气胸和血胸。1例患者发生外渗(因针头误插导致空盐水外渗),17例(9.4%)出现疼痛,41例(22.8%)出现轻微出血如瘀斑。11例(6.1%)发生血栓形成。VPC移除的原因有血栓形成(2例)、败血症(2例)、蜂窝织炎(1例)、皮肤裂开(1例)和患者意愿(1例)。

结论

在住院环境中,VPC植入后立即进行化疗似乎是安全的,不会增加急性和慢性并发症。

相似文献

1
It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting.在住院环境中,通过皮下静脉港导管在植入当日开始化疗似乎是安全的。
Support Care Cancer. 2009 Apr;17(4):399-403. doi: 10.1007/s00520-008-0498-x. Epub 2008 Sep 2.
2
Implantable subcutaneous infusion ports.植入式皮下输注端口
Support Care Cancer. 1993 Mar;1(2):108-10. doi: 10.1007/BF00366905.
3
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.用于长期化疗的完全植入式中心静脉通路导管。一项前瞻性研究,分析333个装置的并发症和成本,最短随访期为180天。
Ann Oncol. 1998 Jul;9(7):767-73. doi: 10.1023/a:1008392423469.
4
Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre.完全植入式静脉输液港系统及其并发症的危险因素:癌症中心的一项为期一年的前瞻性研究。
Eur J Surg Oncol. 2011 Oct;37(10):913-8. doi: 10.1016/j.ejso.2011.06.016. Epub 2011 Aug 9.
5
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.用于实体瘤化疗的、连接到Groshong导管的长期完全植入式中心静脉通路端口:178例使用单一类型装置的经验
Eur J Cancer. 1997 Jul;33(8):1190-4. doi: 10.1016/s0959-8049(97)00039-7.
6
[Complications after insertion of a totally implantable venous access port in patients treated with chemotherapy for head and neck squamous cell carcinoma].[头颈部鳞状细胞癌化疗患者植入全植入式静脉通路端口后的并发症]
Ann Otolaryngol Chir Cervicofac. 2009 Apr;126(2):43-52. doi: 10.1016/j.aorl.2009.02.005. Epub 2009 Mar 25.
7
Mode of chemotherapy does not affect complications with an implantable venous access device.化疗方式不影响植入式静脉通路装置的并发症。
Cancer. 1997 Sep 1;80(5):966-72. doi: 10.1002/(sici)1097-0142(19970901)80:5<966::aid-cncr20>3.0.co;2-t.
8
[Complications after implantation of subcutaneous central venous port].[皮下中心静脉导管植入术后并发症]
Gan To Kagaku Ryoho. 2013 May;40(5):613-6.
9
A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute.对某一机构433例患者上臂端口的效用及并发症进行的回顾性分析。
Int J Clin Oncol. 2016 Jun;21(3):474-82. doi: 10.1007/s10147-015-0917-1. Epub 2015 Oct 27.
10
Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial.外周置入中心静脉导管与植入式港静脉导管在癌症患者中的临床影响:一项开放标签、随机、两中心试验。
Br J Anaesth. 2019 Jun;122(6):734-741. doi: 10.1016/j.bja.2019.01.038. Epub 2019 Apr 17.

引用本文的文献

1
[Clinical Practice and Quality Control Guidelines for Totally Implantable Venous Access Ports in Cancer Patients (2024)].《癌症患者完全植入式静脉输液港临床实践与质量控制指南(2024年)》
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Mar 20;56(2):400-410. doi: 10.12182/20250360602.
2
Application of pocket-first technique for implantation of totally implantable venous access ports.经皮穿刺式隧道口袋技术在完全植入式静脉输液港植入术中的应用
BMC Surg. 2024 Apr 20;24(1):118. doi: 10.1186/s12893-024-02404-4.
3
Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study.

本文引用的文献

1
Subcutaneous venous port implantation in adult patients: a single center experience.成年患者皮下静脉端口植入术:单中心经验
Diagn Interv Radiol. 2006 Jun;12(2):93-8.
2
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.成年癌症患者导管相关血栓形成的发生率、危险因素及预后
J Clin Oncol. 2006 Mar 20;24(9):1404-8. doi: 10.1200/JCO.2005.03.5600.
3
Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports.导管尖端位置作为与皮下输注端口使用相关的血栓形成的危险因素。
成年癌症患者立即使用完全植入式静脉输液港的安全性:一项回顾性单中心研究。
Korean J Clin Oncol. 2021 Dec;17(2):104-110. doi: 10.14216/kjco.21016. Epub 2021 Dec 31.
4
Utility of totally implantable venous access ports in patients with breast cancer.全植入式静脉输液港在乳腺癌患者中的应用价值
Breast J. 2020 Feb;26(2):333-334. doi: 10.1111/tbj.13595. Epub 2019 Sep 20.
5
Is there any effect of first-day usage of a totally implantable venous access device on complications?完全植入式静脉通路装置首日使用对并发症有影响吗?
Int J Clin Oncol. 2015 Dec;20(6):1057-62. doi: 10.1007/s10147-015-0830-7. Epub 2015 Apr 25.
6
Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer.在超声引导下经颈内静脉植入全植入式静脉通路端口对乳腺癌患者是可行且安全的。
World J Surg Oncol. 2014 Dec 8;12:378. doi: 10.1186/1477-7819-12-378.
7
Effect of port-care frequency on venous port catheter-related complications in cancer patients.端口护理频率对癌症患者静脉端口导管相关并发症的影响。
Int J Clin Oncol. 2014 Aug;19(4):761-6. doi: 10.1007/s10147-013-0609-7. Epub 2013 Aug 27.
8
Comparison of subcutaneous central venous port via jugular and subclavian access in 347 patients at a single center.单中心347例患者经颈静脉与锁骨下途径置入皮下中心静脉导管的比较。
Exp Ther Med. 2012 Oct;4(4):675-680. doi: 10.3892/etm.2012.649. Epub 2012 Jul 30.
9
Systematic review: malfunction of totally implantable venous access devices in cancer patients.系统评价:癌症患者完全植入式静脉输液港故障。
Support Care Cancer. 2011 Jul;19(7):883-98. doi: 10.1007/s00520-011-1171-3. Epub 2011 May 10.
Support Care Cancer. 2005 May;13(5):325-31. doi: 10.1007/s00520-004-0723-1. Epub 2004 Nov 5.
4
Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature.癌症患者化疗时经放射学引导植入中心静脉通路端口装置(CVAPD)的长期结局:机构经验及文献综述
Br J Cancer. 2004 Sep 13;91(6):1045-9. doi: 10.1038/sj.bjc.6602082.
5
Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters.接受化疗的血液肿瘤患者颈内静脉导管相关感染和血栓形成:银涂层导管与未涂层导管的前瞻性比较
Cancer. 2002 Jan 1;94(1):245-51. doi: 10.1002/cncr.10199.
6
A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients.一项针对成年肿瘤患者,比较连接标准开放式导管或Groshong导管的中心静脉端口的随机前瞻性试验。
Cancer. 2001 Sep 1;92(5):1204-12. doi: 10.1002/1097-0142(20010901)92:5<1204::aid-cncr1439>3.0.co;2-9.
7
Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life.用于实体组织恶性肿瘤化疗患者的完全植入式静脉输液港系统:一项考察安全性、有效性、成本及对生活质量影响的随机对照临床试验。
J Clin Oncol. 1999 Apr;17(4):1267. doi: 10.1200/JCO.1999.17.4.1267.
8
Complications of subcutaneous infusion port in the general oncology population.普通肿瘤患者皮下输注端口的并发症
Oncology. 1999;56(2):97-102. doi: 10.1159/000011947.
9
Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.5-氟尿嘧啶的时间选择性生化调节:晚期结直肠癌的II期研究
Clin Cancer Res. 1995 Sep;1(9):955-60.
10
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.用于长期化疗的完全植入式中心静脉通路导管。一项前瞻性研究,分析333个装置的并发症和成本,最短随访期为180天。
Ann Oncol. 1998 Jul;9(7):767-73. doi: 10.1023/a:1008392423469.